Angiotensin converting enzyme inhibitors remain the first treatment of choice.

about

Combining Potent Statin Therapy with Other Drugs to Optimize Simultaneous Cardiovascular and Metabolic Benefits while Minimizing Adverse Events.

P2860

Q41190859-6387195E-132D-4E34-868C-4DD39258FD4B

P2860

Angiotensin converting enzyme inhibitors remain the first treatment of choice.

Item

http://www.wikidata.org/entity/Q42617282

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Angiotensin converting enzyme inhibitors remain the first treatment of choice.

@en

Angiotensin converting enzyme inhibitors remain the first treatment of choice.

@nl

type

Item

label

Angiotensin converting enzyme inhibitors remain the first treatment of choice.

@en

Angiotensin converting enzyme inhibitors remain the first treatment of choice.

@nl

prefLabel

Angiotensin converting enzyme inhibitors remain the first treatment of choice.

@en

Angiotensin converting enzyme inhibitors remain the first treatment of choice.

@nl

P1476

Angiotensin converting enzyme inhibitors remain the first treatment of choice.

@en

P2093

Kwang Kon Koh

http://www.w3.org/2001/XMLSchema#string

Pyung Chun Oh

http://www.w3.org/2001/XMLSchema#string

Toshio Hayashi

http://www.w3.org/2001/XMLSchema#string

P2860

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients

Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension

Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study.

Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox.

Angiotensin receptor blockers do not increase risk of myocardial infarction.

Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients

Vascular and metabolic effects of candesartan: insights from therapeutic interventions.

Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction.

P304

237-241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3904/KJIM.2016.026

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ichiro Sakuma

P577

2016-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26932400

http://www.w3.org/2001/XMLSchema#string

P932

4773733

http://www.w3.org/2001/XMLSchema#string

Angiotensin converting enzyme inhibitors remain the first treatment of choice.

about

P2860

P2860

Angiotensin converting enzyme inhibitors remain the first treatment of choice.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932